LAB International Announces Positive Preliminary Results From Additional Phase I Fentanyl TAIFUN(R) Trial

LAVAL, Qc, Oct. 26 /CNW Telbec/ - LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE) ("LAB"), an integrated drug development company with subsidiaries focused on developing therapies for the inhalation market and on providing contract research services, today announced positive preliminary results from an additional comparative Phase I trial for its lead product, Fentanyl TAIFUN(R). The study was conducted in 32 healthy volunteers to obtain additional pharmacokinetic data, and examine dose proportionality using single doses of 100-800 (micro)g of Fentanyl TAIFUN(R). The study also compared the pharmacokinetics of Fentanyl TAIFUN(R) with Actiq(R) 200 (micro)g, the commercially available Fentanyl lozenge.